Thyroid cancer

Related records

Broader conditions (13)

• Cancer
• Cancer or benign tumor
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Endocrine gland neoplasm
• Endocrine system disorder
• Human disease
• Malignant endocrine neoplasm
• Neoplasm
• Neoplastic disease or syndrome
• Thyroid gland disorder
• Thyroid tumor

Narrower conditions (39)

• Columnar cell variant thyroid gland papillary carcinoma
• Differentiated thyroid carcinoma
• Familial medullary thyroid carcinoma
• Familial nonmedullary thyroid carcinoma
• Familial papillary or follicular thyroid carcinoma
• Familial papillary thyroid carcinoma with renal papillary neoplasia
• Intrathyroid thymic carcinoma
• Medullary thyroid gland carcinoma
• Multicentric papillary thyroid carcinoma
• Multiple endocrine neoplasia type 2
• Multiple endocrine neoplasia type 2A
• Multiple endocrine neoplasia type 2B
• Papillary thyroid Microcarcinoma
• Tall cell variant thyroid gland papillary carcinoma
• Thyroid cancer, nonmedullary, 1
• Thyroid cancer, nonmedullary, 2
• Thyroid cancer, nonmedullary, 3
• Thyroid cancer, nonmedullary, 4
• Thyroid cancer, nonmedullary, 5
• Thyroid carcinoma, nonmedullary, with or without cell oxyphilia

Trials (454)

• 11C-Acetate PET/CT Non-FDG-Avid Tumors
• 177Lu-CTR-FAPI for the Treatment of Thyroid Cancer
• 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
• 18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
• 3-D Super Resolution Ultrasound Microvascular Imaging
• 99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer (DTC) Patients
• A Brief Video Intervention to Improve Patient Outcomes Following Radioiodine Treatment
• A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
• A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
• A Follow-up Study of Women Evaluated and Treated for Infertility
• A Multicenter Phase II Pilot Open Label
• A Multicenter Trial of PLA vs. Surgery for Treating PTMC
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
• A New Surgical Strategy to Protect the Inferior Parathyroid
• A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
• A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
• A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
• A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx
• A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression
• A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)

Approved drugs (8)

• Cabozantinib S-malate
• Lenvatinib mesylate
• Levothyroxine sodium
• Selpercatinib
• Sodium iodide I 131
• Sorafenib tosylate
• Thyrotropin alfa
• Vandetanib

Drugs in development (77)

• Abemaciclib Phase 2
• Adalimumab Phase 1
• Adebrelimab Phase 2
• Aldesleukin Phase 1
• Benmelstobart Phase 2
• Bevacizumab Phase 2
• Bexarotene Early phase 1
• Buparlisib Phase 2
• Cabozantinib Phase 3
• Camrelizumab Phase 2
• Capecitabine Phase 2
• Carboplatin Phase 3
• Catequentinib Phase 2
• Catequentinib hydrochloride Phase 2
• Ceritinib Phase 2
• Cisplatin Phase 2
• CM-4307 Phase 3
• Crolibulin Phase 1
• Cyclophosphamide Phase 2
• Dabrafenib Phase 3

Other linked drugs (1)

• Charcoal, activated